Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Image of Cathie Wood via Wikimedia Commons
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? Barchart - Wed Dec 24, 8:00AM CST

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

ARKG : 29.22 (-1.52%)
RXRX : 4.13 (-2.82%)
ARKK : 78.61 (-1.37%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion BayStreet.ca - Fri Dec 12, 8:35AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 0.9054 (-4.89%)
SANA : 4.12 (-6.58%)
ABSI : 3.45 (-3.36%)
RXRX : 4.13 (-2.82%)
TEM : 61.47 (-1.96%)
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks GlobeNewswire - Mon Dec 8, 6:30AM CST

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks...

RXRX : 4.13 (-2.82%)
AI-Powered Platforms Accelerate Healthcare's Preventative Care Wellness Revolution BayStreet.ca - Tue Dec 2, 8:34AM CST

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – The artificial intelligence in healthcare market is projected to expand from $17.2 billion in 2025 to $77.2 billion...

AIDX.TO : 0.83 (-5.68%)
HWAIF : 0.6100 (+5.17%)
WELL.TO : 3.92 (-1.26%)
RXRX : 4.13 (-2.82%)
TEM : 61.47 (-1.96%)
WHTCF : 2.8690 (-8.75%)
ALEN-U.CN : 1.4500 (unch)
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 GlobeNewswire - Mon Dec 1, 7:30AM CST

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a...

RXRX : 4.13 (-2.82%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 FinancialNewsMedia - Tue Nov 18, 7:45AM CST

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.2910 (-0.51%)
ANVS : 3.50 (-2.78%)
RXRX : 4.13 (-2.82%)
ZYME : 26.74 (-0.48%)
NTLA : 9.14 (-3.18%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 GlobeNewswire - Tue Nov 18, 7:45AM CST

MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...

AVAI : 0.2910 (-0.51%)
ANVS : 3.50 (-2.78%)
RXRX : 4.13 (-2.82%)
ZYME : 26.74 (-0.48%)
NTLA : 9.14 (-3.18%)
Recursion Pharmaceuticals: Q3 Earnings Snapshot AP - Wed Nov 5, 5:34AM CST

Recursion Pharmaceuticals: Q3 Earnings Snapshot

RXRX : 4.13 (-2.82%)
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Wed Nov 5, 5:30AM CST

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological...

RXRX : 4.13 (-2.82%)
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth GlobeNewswire - Wed Nov 5, 5:28AM CST

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board...

RXRX : 4.13 (-2.82%)

Barchart Exclusives

This Dividend-Yielding Gold Stock Is Up 184% in 2025. Should You Bet on Higher Gold Prices in 2026? Barchart - Mon Dec 29, 6:30PM CST
Barrick Gold is up big as gold prices continue to hit new records. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot